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Jia Yu Wang1,3, Lei Jin2,3, Xu Guang Yan1, Simonne Sherwin1, Margaret Farrelly1, Yuan Yuan Zhang1,
Fen Liu1, Chun Yan Wang1, Su Tang Guo1, Hamed Yari1, Ting La1, Jennifer McFarlane1, Fu Xi Lei1,
Hessam Tabatabaee1, Jie Zhong Chen1, Amanda Croft1, Chen Chen Jiang2 and Xu Dong Zhang1The effect of MTH1 inhibition on cancer cell survival has been elusive. Here we report that although silencing
of MTH1 does not affect survival of melanoma cells, TH588, one of the first-in-class MTH1 inhibitors, kills
melanoma cells through apoptosis independently of its inhibitory effect on MTH1. Induction of apoptosis by
TH588 was not alleviated by MTH1 overexpression or introduction of the bacterial homolog of MTH1 that has
8-oxodGTPase activity but cannot be inhibited by TH588, indicating that MTH1 inhibition is not the cause of
TH588-induced killing of melanoma cells. Although knockdown of MTH1 did not impinge on the viability of
melanoma cells, it rendered melanoma cells sensitive to apoptosis induced by the oxidative stress inducer
elesclomol. Of note, treatment with elesclomol also enhanced TH588-induced apoptosis, whereas a reactive
oxygen species scavenger or an antioxidant attenuated the apoptosis triggered by TH588. Indeed, the sensitivity
of melanoma cells to TH588 was correlated with endogenous levels of reactive oxygen species. Collectively,
these results indicate that the cytotoxicity of TH588 toward melanoma cells is not associated with its inhibitory
effect on MTH1, although it is mediated by cellular production of ROS.
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Targeting BRAF and mitogen-activated protein kinase/extra-
cellular signal-regulated kinase and co-targeting BRAF and
mitogen-activated protein kinase/extracellular signal-
regulated kinase using specific inhibitors have become the
standard of care for patients with late-stage mutant BRAF
melanomas (Long et al., 2014). However, the benefits are
often of limited duration because of rapid development of
resistance (Robert et al., 2015). The antibodies against im-
mune checkpoints, including CTLA4, PD-1, and PD-L1, can
result in long-lasting melanoma regression, but they are
effective in only a subset of patients (Sharma and Allison,
2015). Although considerable efforts have been made to
improve the efficacy of these existing therapeutic agents, an
alternative approach that has recently gained resurgence in
the treatment of cancer is targeting more generic anomalies
of cancer cells (Alexandrov et al., 2013).
Reactive oxygen species (ROS) are by-products of oxida-
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(Hoidal, 2001). Cancer cells commonly contain elevated
levels of ROS resulting from oncogenic stimulation (Liou and
Storz, 2010). In particular, the increased production of
ROS is a major mechanism of melanomagenesis caused
by UV radiation (Anna et al., 2007). On one hand, ROS
promote cancer cell survival, proliferation, and metastasis
(Gius et al., 2006). On the other, high levels of ROS suppress
tumor growth through inhibition of proliferation and induc-
tion of apoptosis and senescence via damage to DNA
(Ramsey et al., 2006; Takahashi et al., 2006; Zhang et al.,
2011). Incorporation of oxidized deoxyribonucleotide-
triphosphates such as 8-oxo-deoxy-guanine (8-oxo-dGTP)
and 2-OH-deoxy-adenosine into genomic DNA plays
an important role in apoptosis induced by ROS (Ichikawa
et al., 2008). Nevertheless, it seems that cancer cells have
adapted to ROS-mediated tumor suppression without elimi-
nating ROS production and their oncogenic functions
(Rai, 2012).
One of the mechanisms that protects cancer cells from the
cytotoxic effect of high levels of ROS is the expression of
MutT homolog 1 (MTH1), which sanitizes oxidized
deoxyribonucleotide-triphosphates pools through converting
8-oxo-dGTP and 2-OH-deoxy-adenosine into mono-
phosphates, thus preventing their incorporation into genomic
DNA (Ichikawa et al., 2008). Although MTH1 is increased in
many types of cancers (Giribaldi et al., 2015; Obtułowicz
et al., 2010), it is dispensable for normal cells (Tsuzuki,
2001). This has led to the development of MTH1 inhibitors in
the treatment of cancer (Gad et al., 2014; Huber et al., 2014).
Among them is TH588, which kills cancer cells, leading to
impressive therapeutic responses in various human cancerestigative Dermatology. This is an open access
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2278xenografts, including a melanoma explant (Gad et al., 2014;
Huber et al., 2014).
Although MTH1 inhibitors are expected to enter clinical
evaluation (Gad et al., 2014; Huber et al., 2014), the po-
tential of MTH1 as a therapeutic target has recently been
questioned, and the specificity of some existing MTH1 in-
hibitors, including TH588, has been challenged (Kawamura
et al., 2016; Kettle et al., 2016; Petrocchi et al., 2016). In
view of this, we have examined the effect of TH588 and
MTH1 knockdown on melanoma cell survival. We report
here that, although TH588 potently kills melanoma cells
through apoptosis independently of its inhibitory effect on
MTH1, knockdown of MTH1 alone does not affect mela-
noma cell survival, although it renders melanoma cells sen-
sitive to apoptosis induced by the oxidative stress inducer
elesclomol. We also show that induction of apoptosis of
melanoma cells by TH588 is mediated by ROS via activation
of BAD and down-regulation of BCL-2 and MCL-1.
RESULTS
The sensitivity of melanoma cells to TH588 is not associated
with MTH1 expression levels
We characterized the cell death-inducing potential of TH588
in a panel of melanoma cell lines, which carried wild-type
MTH1, as determined by sequencing of all four exons
(including the intron/exonboundaries) of its geneNUDT1, and
had varying status of the most common mutations in BRAF
(BRAFV600E) and NRAS (NRASQ61R) (Figure 1a). There was a
wide variation in the sensitivity of melanoma cells to TH588,
with the half-maximum inhibitory concentration value ranging
from 8.6 mmol/L in Mel-RM to greater than 1,800 mmol/L
in Mel-FH cells (see Supplementary Figure S1a and
Supplementary Table S1 online). The variation was not corre-
lated with MTH1 expression levels, nor was it associated
with the mutational status of BRAF and NRAS (see
Supplementary Figure S1b and c). TH588 did not induce sig-
nificant cell death in any of the three melanocyte lines, HEMa-
LP, HEMn-MP, and HEMn-DP (Figure 1a, and see
Supplementary Figure S2a and b online). The general caspase
inhibitor z-VAD-fmk abolished TH588-induced killing, indi-
cating that cell death was caused by apoptosis (Figure 1b).
TH588 caused caspase-3 activation and cleavage of poly
(adenosine diphosphate-ribose) polymerase in sensitive
(Mel-RM and IgR3) but not resistant (Mel-FH) melanoma cells
(Figure 1c).
As anticipated, TH588 at 8 mmol/L triggered accumulation
of 8-oxodGTP in DNA and increased nuclear 53BP1 foci in
Mel-RM and IgR3 but not Mel-FH cells, indicating that
TH588 inhibited MTH1 activity and caused DNA double-
strand breaks in sensitive but not resistant melanoma cells
(Figure 1d) (Schultz et al., 2000). Consistently, TH588 trig-
gered ATM-dependent phosphorylation of p53 (pSer15-p53)
and induction of the p53 target p21 in Mel-RM and IgR3 but
not Mel-FH cells (Figure 1e) (Jabbur et al., 2002).
The variation in the sensitivity of melanoma cells to TH588
was reflected by long-term survival of Mel-RM, IgR3, and
Mel-FH cells, as shown in clonogenic assays (Figure 1f).
Similarly, it was mirrored in cells grown in three-dimensional
cultures (Figure 1g). TH588 induced varying degrees of
apoptosis in a panel of fresh melanoma isolates, which wasJournal of Investigative Dermatology (2016), Volume 136similarly not associated with the expression levels of MTH1
(see Supplementary Figure S3aec online).
Knockdown of MTH1 does not affect survival of
melanoma cells
We knocked down MTH1 in melanoma cells using two in-
dividual small hairpin RNAs (shRNAs), both of which resul-
ted in reduction in MTH1 protein expression levels by more
than 80% in Mel-RM, IgR3, and Mel-FH cells (Figure 2a).
Although shRNA knockdown of MTH1 reduced its activity, it
did not impinge on cell viability measured on day 2 or day 6
after transduction of shRNAs, even in Mel-RM and IgR3 cells
that were sensitive to TH588 (Figures 2bed, and see
Supplementary Figures S4aec online) (Gad et al., 2014).
Similar to TH588, MTH1 knockdown did not trigger signs of
DNA double-strand breaks in Mel-FH cells (Figure 2b and c,
and see Supplementary Figure S4a and b).
To confirm the results with shRNA knockdown of MTH1,
we carried out small interfering (siRNA) knockdown experi-
ments using two siRNAs with published sequences (Gad
et al., 2014), both of which similarly caused reduction in
MTH1 protein expression levels by more than 80% in Mel-
RM, IgR3, and Mel-FH cells (see Supplementary Figure S5a
online). However, they triggered DNA double-strand breaks
in only Mel-RM and IgR3 but not in Mel-FH cells (see
Supplementary Figure S5b). Similar to shRNA knockdown,
siRNA knockdown of MTH1 did not affect survival of mela-
noma cells measured on day 2 or day 6 after siRNA trans-
fection (see Supplementary Figure S5c) (Gad et al., 2014).
The magnitude of DNA damage caused by MTH1 knock-
down using shRNA or siRNA is less than that resulting from
TH588 treatment in Mel-RM and IgR3 cells (Figure 1d and
2b, and see Supplementary Figures S4b and S5b).
We also carried out clonogenic assays using Mel-RM and
IgR3 cells with or without MTH1 knocked down by shRNA or
siRNA, as previously reported (Gad et al., 2014). The results
showed that knockdown of MTH1 did not affect the clono-
genic potential of Mel-RM and IgR3 cells (Figure 2e, and see
Supplementary Figure S5d).
To test the possibility that the remaining MTH1 protein
after shRNA or siRNA knockdown is sufficient to limit DNA
damage and thus protect cells from apoptosis, we established
a Mel-RM subline that carried an inducible MTH1 shRNA
system in response to tetracycline. The addition of tetracy-
cline achieved visually complete inhibition of MTH1 protein
expression and caused DNA damage (Figure 2f and g).
Nevertheless, it did not impinge on Mel-RM cell survival on
day 2 or day 6 after treatment (Figure 2h). Similarly, it did not
affect the clonogenic activity of Mel-RM cells (Figure 2i).
When Mel-RM, IgR3, and Mel-FH cells with MTH1
knocked down by shRNA or siRNA were exposed to TH588,
it was found that the combination of MTH1 knockdown and
TH588 further enhanced DNA damage and apoptosis in
melanoma cells (Figure 2j, and see Supplementary
Figures S5e and S6 online).
TH588 induces apoptosis of melanoma cells independently
of MTH1
We stably introduced a construct with increasing concen-
trations of wild-type MTH1 cDNA into Mel-RM and IgR3
cells (Figure 3a). Overexpression of MTH1 at even the highest
Figure 1. TH588 induces apoptosis of melanoma cells. (a) Various sensitivities of melanoma cell and melanocyte lines to TH588. (b) Killing of melanoma cells
by TH588 was inhibited by z-VAD-fmk. (c) TH588 activated caspase-3 and cleaved PARP in IgR3 and Mel-RM cells. (d) TH588 triggered nuclear accumulation
of 8-oxo-dGTP and 53BP1 foci in Mel-RM and IgR3 cells. Green, 8-oxo-dGTP; red, 53BP1; blue, DAPI (nuclei). Numbers represent relative staining intensity.
Scale bar ¼ 25 mm. (e) TH588 induced p53pS15 and p21 in Mel-RM and IgR3 cells. (f) TH588 inhibited the clonogenic potential in IgR3 and Mel-RM. Scale
bar ¼ 1 cm. (g) TH588 kills IgR3 and Mel-RM cells grown in three-dimensional culture. Green, living cells; red, dead cells. Scale bar ¼ 25 mm. n ¼ 3, mean 
standard error of the mean or representative. *P < 0.05, Student t test. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; h, hours; hrs, hours; M, mutant; M,
mol/L; PARP, poly (adenosine diphosphate-ribose) polymerase; W, wild-type.
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Figure 2. MTH1 knockdown does not affect melanoma cell survival. (a) shRNA knockdown of MTH1 (b) triggered nuclear accumulation of 8-oxo-dGTP and
53BP1 foci, (c) induced p53pS15 and p21, but did not affect (d) melanoma cell survival or (e) the clonogenic potential. (f) Tetracycline-triggered MTH1 silencing
(g) caused DNA damage, but did not affect (h) survival or (i) the clonogenic potential of Mel-RM cells carrying an inducible MTH1 shRNA system. (j) Melanoma
cells with MTH1 knocked down by shRNAwere more sensitive to TH588. n ¼ 3, mean  standard error of the mean or representative; *P < 0.05, Student t test.
(b, g) Scale bar ¼ 25 mm. (e, i) Scale bar ¼ 1 cm. Numbers represent either relative levels MTH1 or staining intensity. 8-oxo-dGTP, 8-oxo-deoxy-guanine; Ctrl,
control; shRNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; small hairpin RNA; Tet, tetracycline; UT, untreated.
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Figure 3. TH588 induces apoptosis of melanoma cells independently of MTH1. (a) MTH1 expression in melanoma cells transduced with a construct with
increasing concentrations of MTH1 cDNA. (b) Overexpression of MTH1 did not protect melanoma cells against TH588. (c) MTH1 overexpression did not
significantly inhibit TH588-induced nuclear accumulation of 8-oxo-dGTP and 53BP1 foci in melanoma cells. Green, 8-oxo-dGTP; red, 53BP1; blue, DAPI
(nuclei). Numbers represent relative staining intensity of 8-oxo-dGTP or 53BP1. Scale bar ¼ 25mm. (d) myc-Tagged MutT expression in melanoma cells
introduced with myc-tagged mitochondrial MutT (MutT-m) or MutT-m plus nuclear MutT (MutT-mn). (e) MutT did not protect melanoma cells against TH588.
n ¼ 3, mean  standard error of the mean or representative. Statistical analysis was performed using Student t test. 8-oxo-dGTP, 8-oxo-deoxy-guanine; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; h, hours; M, mol/L; MutT, bacterial homologue of MTH1.
JY Wang et al.
ROS in the Response of Melanoma to TH588levels achieved did not significantly inhibit TH588-induced
apoptosis (Figure 3b). Similarly, it only modestly inhibited
TH588-triggered DNA damage (Figure 3c). These results
suggest that mechanisms other than inhibition of MTH1 play
a major role in DNA damage and apoptosis induced by
TH588 in melanoma cells.
To examine the likelihood that TH588 at the concentration
used also inhibited exogenously introduced MTH1, we
expressed the bacterial homologue of MTH1 (MutT) that has
8-oxo-dGTPase activity but cannot be inhibited by TH588 in
melanoma cells as described previously (Figure 3d) (Gad
et al., 2014). Expression of mitochondrial MutT or co-
expression of mitochondrial and nuclear MutT did not
rescue melanoma cells from cell death caused by TH588
(Figure 3e), further confirming that TH588 kills melanoma
cells through mechanisms that are not associated with inhi-
bition of MTH1.Oxidative stress determines the sensitivity of melanoma
cells to TH588
Because inhibition of MTH1 causes DNA damage by ROS
(Gad et al., 2014), we examined whether induction of ROS
affects the potential cytotoxicity of MTH1 knockdown toward
melanoma cells. Although the oxidative stress inducer ele-
sclomol did not affect survival of Mel-RM and IgR3 cells
transduced with the control shRNA, it induced apoptosis of
the cells with MTH1 knocked down (Figures 2a and 4a) (Qu
et al., 2010). Moreover, it triggered apoptosis, albeit moder-
ately, in Mel-FH cells with MTH1 knocked down (Figure 4a).
We also examined whether TH588-induced apoptosis of
melanoma cells is caused by oxidative stress. Indeed, ele-
sclomol enhanced apoptosis induced by TH588 (Figure 4b).
In contrast, the ROS scavenger N-acetyl-L-cysteine or
the antioxidant glutathione attenuated apoptosis induced
by TH588 (Figure 4c). These results show that thewww.jidonline.org 2281
Figure 4. Oxidative stress determines
the sensitivity of melanoma cells to
TH588. (a) Elesclomol induced cell
death in melanoma cells with MTH1
knocked down. (b) Elesclomol
enhanced melanoma cell death
induced by TH588. (c) GSH and NAC
protected melanoma cells against
TH588. n ¼ 3, mean  SEM; * P <
0.05, Student t test. Ctrl, control; GSH,
glutathione; h, hours; M, mol/L; NAC,
N-acetyl-L-cysteine; shRNA, small
hairpin RNA.
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TH588 is associated with the severity of oxidative stress and
suggest that TH588 kills melanoma cells by interfering with a
mechanism(s), which, similar to MTH1, protects melanoma
cells from oxidative stress-induced killing.
Sensitivity of melanoma cells to TH588 is correlated with
the levels of endogenous ROS
We quantitated ROS production in melanoma cell lines by
staining with the fluorescent ROS probe DHR123 (Lee et al.,
2015). As anticipated, the levels of ROS were commonly
higher in melanoma cell lines than melanocyte lines, which
were positively correlated with the sensitivity of melanoma
cells to apoptosis induced by TH588 (Figure 5a and b). The
levels of carbonylated proteins that reflect ROS levels were
similarly correlated with TH588-induced apoptosis
(Figure 5c and d) (Dalle-Donne et al., 2003). The relationshipJournal of Investigative Dermatology (2016), Volume 136between the levels of ROS and the sensitivity of melanoma
cells to TH588 was consolidated in the panel of fresh mela-
noma isolates (Figure 5e, and see Supplementary Figures S3a
and S7 online).
Activation of BAD and down-regulation of BCL-2 and MCL-1
mediate apoptosis of melanoma cells induced by TH588
TH588 activated the mitochondrial apoptotic pathway, as
shown by induction of caspase-9 activation, reduction in the
mitochondrial membrane potential, and mitochondrial
release of apoptogenic proteins in Mel-RM and IgR3 cells
(see Supplementary Figure S8a and b online) (Kroemer et al.,
2007). However, it did not affect the expression of PUMA and
NOXA, which are known to be responsive to DNA damage
(see Supplementary Figure S8c) (Zinkel et al., 2006). Instead,
it caused dephosphorylation (activation) of BAD and down-
regulation of BCL-2 and MCL-1 in Mel-RM and IgR3 but
Figure 5. The sensitivity of melanoma
cells to TH588 is correlated with the
levels of endogenous ROS. (a) Various
levels of endogenous ROS in
melanoma cell and melanocyte lines.
(b) The sensitivity of melanoma cells
to TH588 was correlated with
endogenous ROS levels. (c) Relative
levels of carbonylated proteins in
melanoma cell and melanocyte lines.
(d) The sensitivity of melanoma cells
to TH588 was correlated with relative
carbonylated protein levels. (e) The
sensitivity of fresh melanoma isolates
to TH588 was correlated with
endogenous ROS levels (see
Supplementary Figure S7). n ¼ 3,
mean  standard error of the mean or
representative. *P < 0.05, Student t
test. M, mol/L; ROS, reactive oxygen
species.
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did not cause any of these changes, it enabled elesclomol to
activate BAD and down-regulate BCL-2 and MCL-1
(Figure 6b, and see Supplementary Figure S8d and). The
role of BAD in apoptosis induced by TH588 or by elesclomol
along with MTH1 knockdown was confirmed by shRNA
knockdown of BAD (Figures 6cee). On the other hand,
overexpression of MCL-1 or BCL-2 protected Mel-RM and
IgR3 cells from apoptosis induced by TH588 or elesclomol in
combination with MTH1 knockdown (Figures 6feh).
DISCUSSION
Although a number of MTH1 inhibitors, including TH588 and
SCH51344, have been shown to kill cancer cells potently,
leading to impressive therapeutic responses in various human
cancer xenografts (Gad et al., 2014; Huber et al., 2014),
recent studies have cast doubt on the potential of MTH1 as a
therapeutic target (Kawamura et al., 2016; Kettle et al., 2016;
Petrocchi et al., 2016). This is because, unlike reported first-
in-class MTH1 inhibitors, some newly synthesized specific
MTH1 inhibitors did not have any inhibitory effect on cell
survival (Kawamura et al., 2016; Kettle et al., 2016). More-
over, knockdown of MTH1 or its knockout did not impinge onsurvival of cancer cells (Kawamura et al., 2016; Kettle et al.,
2016). Although the reason(s) leading to these inconsistent
observations remains unclear, the experimental conditions
used by different investigators varied considerably (Brautigam
et al., 2016; Gad et al., 2014; Gao et al., 2015; Huber et al.,
2014; Kawamura et al., 2016). Regardless, because
dysfunctional redox regulation is of particular importance in
the pathogenesis of melanoma (Hall et al., 2013), we were
prompted to examine the effect of MTH1 inhibition on sur-
vival of melanoma cells.
Our results indicate that TH588 induces apoptosis of
melanoma cells independently of its inhibitory effect on
MTH1 (Kawamura et al., 2016; Kettle et al., 2016). This is
primarily for two reasons. First, although TH588 induced
apoptosis of melanoma cells, MTH1 knockdown using mul-
tiple shRNAs and siRNAs did not affect the viability of mel-
anoma cells that were sensitive to TH588-induced apoptosis,
which was tested in diverse experimental settings at various
time points after introduction of shRNAs or siRNAs (Gad
et al., 2014). Second, overexpression of wild-type MTH1 or
introduction of MutT that has 8-oxo-dGTPase activity but
cannot be inhibited by TH588 did not rescue melanoma cells
from killing by TH588.www.jidonline.org 2283
Figure 6. BAD activation and BCL-2 and MCL-1 down-regulation mediate TH588-induced apoptosis of melanoma cells. (a) TH588 activated BAD and down-
regulated BCL-2 and MCL-1 in IgR3 and Mel-RM but not Mel-FH cells. (b) Elesclomol triggered BAD activation and BCL-2 and MCL-1 up-regulation in
melanoma cells with MTH1 knocked down. (c) shRNA knockdown of BAD inhibited (d) TH588-induced killing of IgR3 and Mel-RM cells and (e) elesclomol-
triggered killing in IgR3 and Mel-RM cells with MTH1 knocked down. (f) Overexpression of MCL-1 or BCL-2 protected (g) IgR3 and Mel-RM cells from TH588-
induced killing and (h) elesclomol-triggered killing in IgR3 andMel-RMcellswithMTH1knockeddown.n¼3,mean standard error of themeanor representative.
*P < 0.05, Student t test. Ctrl, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; h, hours; hrs, hours; M, mol/L; shRNA, small hairpin RNA.
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ROS in the Response of Melanoma to TH588Although MTH1 knockdown, similar to treatment with
TH588, resulted in DNA damage in melanoma cells that
were sensitive, but not in those resistant, to TH588-induced
apoptosis, the magnitude of DNA damage caused by MTH1
knockdown is less than that resulting from TH588. Given our
results showing that knockdown of MTH1 does not affect
melanoma cell survival, these observations suggest that,
despite its inhibitory effect on MTH1, TH588 also triggers
DNA damage and apoptosis in melanoma cells through
inhibiting targets that share similar roles with MTH1 in pro-
tecting melanoma cells from oxidative stress (Brautigam
et al., 2016). In support of this, inhibition of MTH1 sensi-
tized melanoma cells to TH588-induced apoptosis. More-
over, although the oxidative stress inducer elesclomol
rendered melanoma cells sensitive to MTH1 knockdown, it
also enhanced apoptosis induced by TH588. On the other
hand, a ROS scavenger or an antioxidant attenuated mela-
noma cell death caused by TH588.
The molecular target(s) responsible for TH588-induced
killing of melanoma cells remains undefined, but it is
known that OGG1 and MUTYH are important in repair of 8-
oxo-dGTP and 2-OH-deoxy-adenosine lesions in DNA
(Nakabeppu, 2014). However, overexpression of OGG1 or
MUTYH did protect cells from TH588-induced cell death
(Gad et al., 2014). Regardless, the potential of TH588 as an
antimelanoma drug warrants further investigations, because
TH588 did not have significant toxicity toward melanocytes
and other types of normal cells (Gad et al., 2014). The finding
that the sensitivity of melanoma cells to TH588 was not
related to the most common mutations in BRAF and NRAS
suggests that these oncogenic drivers do not pose a barrier for
application of TH588 in the treatment of melanoma. Because
melanoma cells, similar to many other types of cancer cells,
contain elevated levels of ROS (Liou and Storz, 2010; Myant
et al., 2013; Nogueira and Hay, 2013), it is plausible that the
sensitivity of melanoma cells to TH588 is correlated with
the endogenous levels of ROS. This not only suggests that the
constitutive oxidative stress determines the potency of TH588
but also implies that ROS levels may be a biomarker for
prediction of the response of melanomas to the compound.
Our results showed that TH588-induced apoptosis of
melanoma cells was mediated by activation of BAD and
down-regulation of BCL-2 and MCL-1. This may be associ-
ated with high levels of ROS that inhibit protein kinase B
activation and promote activation of c-Jun N-terminal kinase
and p38, which in turn contribute to BAD activation and
down-regulation of BCL-2 and MCL-1 caused by TH588
(Zhang et al., 2011). Moreover, inhibition of NF-kB by high
levels of ROS may also be involved (Xu et al., 2015).
Elesclomol-induced apoptosis in melanoma cells with MTH1
knockdown was also mediated by BAD, consistent with the
finding that inhibition of MTH1 sensitizes melanoma cells to
oxidative stress.
The results from this study bear several implications about
the potential usefulness of TH588 and MTH1 inhibition in the
treatment of melanoma: (i) TH588-induced apoptosis of
melanoma cells is not associated with its inhibitory effect on
MTH1, (ii) TH588 remains a promising candidate for the
treatment of melanoma, (iii) MTH1 inhibition in combination
with oxidative stress inducers may be a useful approach inmelanoma treatment, and (iv) the endogenous levels of ROS
are a potential biomarker for predicting the response of
melanomas to TH588 and MTH1 inhibition in combination
with oxidative stress inducers.
MATERIALS AND METHODS
Cell culture
Human melanoma cell lines and human melanocyte lines were
obtained and cultured as described previously (Jiang et al., 2010).
Human fresh melanoma isolates were prepared from surgical spec-
imens according to the published method (Nguyen et al., 2001).
Studies using human tissues were approved by the Human Research
Ethics Committee of The University of Newcastle, Australia (X11-
0023&HREC/11/RPA) and are in agreement with the guidelines set
forth by Declaration of Helsinki. All participants provided written
informed consent.
Three-dimensional culture
Three-dimensional culture was performed using the hanging drop
technique, as previously described (Tay et al., 2015). Cells were
stained with calcein AM (living cell stain) and ethidium homodimer-
1 (dead cell stain) (Life Technologies, Scoresby, Victoria, Australia)
for 24 hours, followed by treatment.
Antibodies and reagents
Antibodies and reagents used are listed in Supplementary Tables S1,
S2, and S3 online.
Cell viability
The CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, San
Luis Obispo, CA) was used according to the manufacturer’s
instructions.
Western blotting
Western blotting was carried out as described previously (Jiang et al.,
2011). The intensity of Western blot bands was quantitated with
ImageReader LAS-4000 (Fujifilm, Tokyo, Japan).
Preparation of mitochondrial and cytosolic fractions
Methods used for subcellular fraction were similar to the methods
previously described (Wang et al., 2016).
Dihydrorhodamine 123 staining assays
ROS were measured by detecting the fluorescent intensity of
oxidant-sensitive probe dihydrorhodamine 123 (Lee et al., 2015),
which was recorded using a Synergy 2 multidetection microplate
reader (BioTek, Winooski, VT) at excitation of 485 nm and emission
of 538 nm.
Protein carbonyl assays
Protein carbonyls were measured from homogenates using 2,4-
dinitrophenylhydrazine (DNPH) derivatization with a Protein
Carbonyl Assay Kit (Abcam, Cambridge, MA) according to the
manufacturer’s instructions (Dalle-Donne et al., 2003).
Immunofluorescence
Immunofluorescence staining was carried out as described previ-
ously (Zhang et al., 2000). Quantification was done by manual
counting of positive cells under a fluorescence microscope (Carl
Zeiss, Sydney, Australia).
Statistics
Statistical analysis was performed using JMP Statistics Made Visual
software (SAS, Cary, NC). Student t test was used to assess differ-
ences between different groups. A P-value less than 0.05 was
considered statistically significant.www.jidonline.org 2285
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